Another study using 59 clinical metastatic cutaneous melanoma samples found that p16INK4α was methylated in 25% of samples (n = 15) and that promoter methylation was significantly overrepresented in samples harboring NRAS mutations (120). Here, CDKN2A is linked to cutaneous melanoma.